SCHEMBL7597199

SCHEMBL7597199

O=[PH](O)CP(=O)(O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methane SCHEMBL10582765 0.97
Ethane SCHEMBL8949916 0.94 KDM4E (0.35)
Methylamine SCHEMBL9161547 0.91 LAP3 (0.35)
Pyridine SCHEMBL8706837 0.79 TSHR (0.38)
Toluene SCHEMBL8949748 0.76 LMNA (0.42)
SCHEMBL9402428 0.75
SCHEMBL11693402 0.71
SCHEMBL14580424 0.69
Medronic Acid SCHEMBL7755429 0.69 KDM4E (0.71)
SCHEMBL14252385 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1072965-C Improved topical delivery of drugs PROCTER & GAMBLE (US) 2001-10-17 CN claimed
CN-1091317-A Improve the part input of medicine PROCTER & GAMBLE (US) 1994-08-31 CN claimed
EP-0573604-A1 METHODS FOR THE TREATMENT OF OSTEOPOROSIS. NORWICH EATON PHARMA (US) 1993-12-15 EP claimed
WO-1992014474-A1 METHODS FOR THE TREATMENT OF OSTEOPOROSIS NORWICH EATON PHARMACEUTICALS, INC. (US) 1992-09-03 WO claimed
US-20230129793-A1 KITS AND DEVICES BIOFIDELITY LTD (GB) 2023-04-27 US disclosed
CN-114945578-A Compounds as CD73 inhibitors 博奥阿迪斯生物科技公司 2022-08-26 CN disclosed
EP-3377504-B1 CYCLAM BASED COMPOUNDS, THEIR CONJUGATES, CO-ORDINATION COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, METHOD OF PREPARATION AND USE THEREOF UNIV KARLOVA (CZ) 2020-08-19 EP disclosed
US-8772268-B2 Bisphosphonamidate prodrugs and uses thereof THE JOHNS HOPKINS UNIVERSITY (US) 2014-07-08 US disclosed
WO-2009116044-A2 COMPOUNDS FOR TREATING BACTERIAL INFECTIONS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2009-09-24 WO disclosed
WO-2001044260-A9 NOVEL PURINES ARIAD PHARMA INC (US) 2002-07-04 WO disclosed
EP-1158987-A1 METHODS OF INCREASING BONE VOLUME USING NON-NATURALLY-OCCURRING FP SELECTIVE AGONISTS AND ANTIRESORPTIVE COMPOUNDS THE PROCTER & GAMBLE COMPANY (US) 2001-12-05 EP disclosed
CN-1072965-C Improved topical delivery of drugs PROCTER & GAMBLE (US) 2001-10-17 CN disclosed
EP-0586521-A1 CALCIUM, TRACE MINERAL, VITAMIN D AND DRUG THERAPY COMBINATIONS THE PROCTER & GAMBLE COMPANY (US) 1994-03-16 EP disclosed
EP-0537008-A1 Use of biphosphonates for the manufacture of a medicament for blocking neoplastic transformation of cells induced by ras oncogenes E.R. SQUIBB &amp; SONS, INC. (US) 1993-04-14 EP disclosed
WO-1992021355-A1 CALCIUM, TRACE MINERAL, VITAMIN D AND DRUG THERAPY COMBINATIONS THE PROCTER & GAMBLE COMPANY (US) 1992-12-10 WO disclosed
EP-0514124-A2 Use of phosphonomethylphosphinate squalene synthetase inhibitors for the manufacture of a medicament for the lowering cholesterol E.R. SQUIBB &amp; SONS, INC. (US) 1992-11-19 EP disclosed
EP-0514124-A2 Use of phosphonomethylphosphinate squalene synthetase inhibitors for the manufacture of a medicament for the lowering cholesterol E.R. SQUIBB &amp; SONS, INC. (US) 1992-11-19 EP disclosed
EP-0298553-B1 METHYLENE PHOSPHONOALKYLPHOSPHINATES, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM Norwich Eaton Pharmaceuticals, Inc. (US) 1992-01-15 EP disclosed
EP-0351897-A2 Skin penetration system for salts of amine-functional drugs THE PROCTER & GAMBLE COMPANY (US) 1990-01-24 EP disclosed
EP-0298553-A1 Methylene phosphonoalkylphosphinates, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism Norwich Eaton Pharmaceuticals, Inc. (US) 1989-01-11 EP disclosed